Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 15/20 | 0.59 |
| ▸ | DDB1 | Q16531 | 8/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22158608 | 1.00 | CRBN (0.59) | CRBNDDB1ALDH1A1KDM4EGAA | |
| SCHEMBL22158607 | 1.00 | CRBN (0.59) | CRBNDDB1ALDH1A1KDM4EGAA | |
| SCHEMBL19359331 | 0.92 | CRBN (0.62) | CRBNDDB1ALDH1A1KDM4EGAA | |
| SCHEMBL29923129 | 0.92 | CRBN (0.62) | CRBNDDB1ALDH1A1KDM4EGAA | |
| SCHEMBL26930417 | 0.82 | ALDH1A1 (0.46) | CRBNDDB1ALDH1A1KDM4EGAA | |
| SCHEMBL24411098 | 0.79 | CRBN (0.70) | CRBNDDB1ALDH1A1IKZF3CHRM2 | |
| SCHEMBL26930468 | 0.79 | HTR2C (0.51) | CRBNDDB1ALDH1A1KDM4EGAA | |
| SCHEMBL11829199 | 0.78 | CRBN (0.52) | CRBNDDB1ALDH1A1KDM4EGAA | |
| SCHEMBL31426173 | 0.78 | CRBN (0.51) | CRBNDDB1ALDH1A1KDM4EGAA | |
| SCHEMBL31443820 | 0.78 | CRBN (0.64) | CRBNALDH1A1KDM4EGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199638-A1 | GLUTARIMIDES FOR MEDICAL TREATMENT | C4 THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | US | disclosed |
| US-11802131-B2 | Glutarimides for medical treatment | C4 THERAPEUTICS, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-20200207783-A1 | GLUTARIMIDES FOR MEDICAL TREATMENT | C4 THERAPEUTICS, INC. (US) | 2020-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11802131-B2 | Glutarimides for medical treatment | CRBN, GCDH, GCLC | CRBN 1/4885DDB1 414/4885ALDH1A1 1593/4885 |
| US-20240199638-A1 | GLUTARIMIDES FOR MEDICAL TREATMENT | CRBN, GCDH, GCLC | CRBN 1/4885DDB1 414/4885ALDH1A1 1593/4885 |
| US-20200207783-A1 | GLUTARIMIDES FOR MEDICAL TREATMENT | CRBN, GCDH, GCLC | CRBN 1/4885DDB1 414/4885ALDH1A1 1593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.